病毒性气道感染中的抗生素治疗(ATHENIAN):一项评估停用抗生素有效性与安全性的开放标签随机实用试验研究方案
ATHENIAN是一项正在进行的多中心、开放标签、实用型随机非劣效性试验,计划在挪威10个中心招募400例因急性呼吸道感染入院并启动抗生素治疗、且PCR检测出流感病毒、人偏肺病毒、呼吸道合胞病毒或副流感病毒的成人患者。患者随机分为停用抗生素组或继续抗生素组,主要结局为随机化后120小时的早期临床应答,即存活且症状改善且未接受补救抗菌治疗。研究假设停用抗生素不劣于继续使用,旨在为基于多重核酸检测结果的抗菌药物降阶梯策略提供证据。
要点
- 针对PCR确诊呼吸道病毒且无明确细菌感染证据的成人住院患者,评估停用抗生素是否安全。
- 主要结局为随机化后120小时早期临床应答:存活、症状改善且未用补救抗菌治疗。
- 计划招募400例,在挪威10个中心进行开放标签、实用型随机非劣效性试验。
核心结论
- 研究假设在PCR确诊呼吸道病毒且无明确细菌感染证据的成人住院患者中,停用抗生素治疗不劣于继续使用。
研究设计与样本
- ATHENIAN为正在进行的多中心、开放标签、实用型、随机非劣效性试验。
- 计划在挪威10个研究站点招募400例成年患者,入选条件为入院时启动抗生素治疗且PCR检测阳性。
- PCR阳性病原体限定为流感病毒、人偏肺病毒、呼吸道合胞病毒或副流感病毒。
- 参与者随机分为干预组(停用抗生素)或对照组(由主治医师酌情继续抗生素治疗)。
主要发现
- 主要结局为随机化后120小时评估的早期临床应答,定义为存活且症状改善且未接受补救抗菌治疗。
- 次要结局包括全因住院死亡和30天死亡、住院时长、抗生素治疗天数、住院期间补救抗生素治疗、出院后30天内因疑似气道感染的新抗生素治疗以及出院后30天内再入院。
临床怎么用
- 该试验旨在为基于多重核酸扩增检测结果的抗菌药物降阶梯策略提供安全性和有效性证据。
- 研究结果可能影响治疗算法和抗生素处方实践,有助于减少不适当抗生素使用和抗菌药物耐药的发生。
局限性
- 研究为开放标签设计,对照组继续抗生素治疗由主治医师酌情决定。
- 研究方案尚未报告实际入组完成情况和试验结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Reducing inappropriate use of antibiotics is essential to combat antimicrobial resistance. Antibiotics are widely prescribed upon hospital admission for acute respiratory infections, but it remains unknown whether it is safe to discontinue antibiotics when a respiratory virus is detected in these patients. With this randomized trial, we aim to assess the efficacy and safety of discontinuing antibiotic therapy in patients admitted to the hospital with a polymerase chain reaction test positive for respiratory virus and no clear evidence of bacterial infection. METHODS: ATHENIAN is an ongoing multicenter, open-label, pragmatic, randomized non-inferiority trial. We aim to recruit 400 adult patients initiated on antibiotic therapy at admittance to one of the 10 study sites in Norway and with a positive polymerase chain reaction test for influenza virus, human metapneumovirus, respiratory syncytial virus, or parainfluenza virus. The participants are randomized to intervention, discontinuation of antibiotic therapy, or control, continuation of antibiotic therapy at the discretion of the treating physician. We hypothesize that discontinuation of antibiotic therapy is safe and non-inferior to continuation of antibiotic therapy. The primary outcome, assessed at 120 h after randomization, is early clinical response, defined as survival with symptom improvement without receipt of rescue antibacterial therapy. Secondary outcomes include all-cause in-hospital and 30-day mortality, duration of hospital admission, days of therapy with antibiotics, rescue antibiotic therapy during hospital admission, new antibiotic therapy for presumed airway infection up to 30 days after hospital discharge, and hospital readmissions within 30 days after hospital discharge. DISCUSSION: To our knowledge, ATHENIAN is the first randomized controlled trial assessing the safety and efficacy of antimicrobial de-escalation based on multiplex nucleic acid amplification test results. Addressing this knowledge gap using a pragmatic study design will provide valuable insights that may influence treatment algorithms and antibiotic prescription practices. The study has the potential to contribute to a reduction in the inappropriate use of antibiotics and the emergence of antimicrobial resistance. TRIAL REGISTRATION: ClinicalTrials.gov NCT05045612. Registered on September 7, 2021.
引用
- Hovind MJ, Berdal JE, Benth JŠ, et al. Antibiotic therapy in viral airway infections (ATHENIAN): study protocol for an open labeled randomized controlled pragmatic trial to evaluate the efficacy and safety of discontinuing antibiotic therapy in adult patients infected with respiratory viruses. Trials. 2026. PMID: 42015169. doi:10.1186/s13063-026-09730-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。